Global Immunosuppressant Drugs

Immunosuppressant Drugs Comprehensive Study by End-users (Hospitals, Clinics, Others), Indication (Organ Transplantation, Autoimmune Disorders, Non-autoimmune Inflammatory Diseases), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), Drug Class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, MTOR Inhibitors, Anti-Proliferative Agents, Others) Players and Region - Global Market Outlook to 2030

Immunosuppressant Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled

Report Objectives / Segmentation Covered

By End-users
  • Hospitals
  • Clinics
  • Others

By Indication
  • Organ Transplantation
  • Autoimmune Disorders
  • Non-autoimmune Inflammatory Diseases

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Drug Class
  • Corticosteroids
  • Monoclonal Antibodies (mAbs)
  • Calcineurin Inhibitors
  • MTOR Inhibitors
  • Anti-Proliferative Agents
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Autoimmune Disorders such as Arthritis
      • 3.2.2. Increased Number of DIagnostic Centres and Hospitals
      • 3.2.3. Rise in the Healthcare Infrastructure in Developing Regions
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations about Drugs
    • 3.4. Market Trends
      • 3.4.1. Rise in the Number of Online Pharmacies
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immunosuppressant Drugs, by End-users, Indication, Distribution Channel, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Immunosuppressant Drugs (Value)
      • 5.2.1. Global Immunosuppressant Drugs by: End-users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Immunosuppressant Drugs by: Indication (Value)
        • 5.2.2.1. Organ Transplantation
        • 5.2.2.2. Autoimmune Disorders
        • 5.2.2.3. Non-autoimmune Inflammatory Diseases
      • 5.2.3. Global Immunosuppressant Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Immunosuppressant Drugs by: Drug Class (Value)
        • 5.2.4.1. Corticosteroids
        • 5.2.4.2. Monoclonal Antibodies (mAbs)
        • 5.2.4.3. Calcineurin Inhibitors
        • 5.2.4.4. MTOR Inhibitors
        • 5.2.4.5. Anti-Proliferative Agents
        • 5.2.4.6. Others
      • 5.2.5. Global Immunosuppressant Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Immunosuppressant Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma Inc. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Holding AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi S.A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Allergan, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Veloxis Pharmaceuticals A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Immunosuppressant Drugs Sale, by End-users, Indication, Distribution Channel, Drug Class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Immunosuppressant Drugs (Value)
      • 7.2.1. Global Immunosuppressant Drugs by: End-users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Immunosuppressant Drugs by: Indication (Value)
        • 7.2.2.1. Organ Transplantation
        • 7.2.2.2. Autoimmune Disorders
        • 7.2.2.3. Non-autoimmune Inflammatory Diseases
      • 7.2.3. Global Immunosuppressant Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Immunosuppressant Drugs by: Drug Class (Value)
        • 7.2.4.1. Corticosteroids
        • 7.2.4.2. Monoclonal Antibodies (mAbs)
        • 7.2.4.3. Calcineurin Inhibitors
        • 7.2.4.4. MTOR Inhibitors
        • 7.2.4.5. Anti-Proliferative Agents
        • 7.2.4.6. Others
      • 7.2.5. Global Immunosuppressant Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immunosuppressant Drugs: by End-users(USD Million)
  • Table 2. Immunosuppressant Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 3. Immunosuppressant Drugs Clinics , by Region USD Million (2018-2023)
  • Table 4. Immunosuppressant Drugs Others , by Region USD Million (2018-2023)
  • Table 5. Immunosuppressant Drugs: by Indication(USD Million)
  • Table 6. Immunosuppressant Drugs Organ Transplantation , by Region USD Million (2018-2023)
  • Table 7. Immunosuppressant Drugs Autoimmune Disorders , by Region USD Million (2018-2023)
  • Table 8. Immunosuppressant Drugs Non-autoimmune Inflammatory Diseases , by Region USD Million (2018-2023)
  • Table 9. Immunosuppressant Drugs: by Distribution Channel(USD Million)
  • Table 10. Immunosuppressant Drugs Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 11. Immunosuppressant Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Immunosuppressant Drugs Online , by Region USD Million (2018-2023)
  • Table 13. Immunosuppressant Drugs Others , by Region USD Million (2018-2023)
  • Table 14. Immunosuppressant Drugs: by Drug Class(USD Million)
  • Table 15. Immunosuppressant Drugs Corticosteroids , by Region USD Million (2018-2023)
  • Table 16. Immunosuppressant Drugs Monoclonal Antibodies (mAbs) , by Region USD Million (2018-2023)
  • Table 17. Immunosuppressant Drugs Calcineurin Inhibitors , by Region USD Million (2018-2023)
  • Table 18. Immunosuppressant Drugs MTOR Inhibitors , by Region USD Million (2018-2023)
  • Table 19. Immunosuppressant Drugs Anti-Proliferative Agents , by Region USD Million (2018-2023)
  • Table 20. Immunosuppressant Drugs Others , by Region USD Million (2018-2023)
  • Table 21. South America Immunosuppressant Drugs, by Country USD Million (2018-2023)
  • Table 22. South America Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 23. South America Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 24. South America Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 25. South America Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 26. Brazil Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 27. Brazil Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 28. Brazil Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 29. Brazil Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 30. Argentina Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 31. Argentina Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 32. Argentina Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 33. Argentina Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 34. Rest of South America Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 35. Rest of South America Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 36. Rest of South America Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 37. Rest of South America Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 38. Asia Pacific Immunosuppressant Drugs, by Country USD Million (2018-2023)
  • Table 39. Asia Pacific Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 40. Asia Pacific Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 41. Asia Pacific Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 42. Asia Pacific Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 43. China Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 44. China Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 45. China Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 46. China Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 47. Japan Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 48. Japan Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 49. Japan Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 50. Japan Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 51. India Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 52. India Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 53. India Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 54. India Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 55. South Korea Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 56. South Korea Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 57. South Korea Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 58. South Korea Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 59. Taiwan Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 60. Taiwan Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 61. Taiwan Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 62. Taiwan Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 63. Australia Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 64. Australia Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 65. Australia Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 66. Australia Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 71. Europe Immunosuppressant Drugs, by Country USD Million (2018-2023)
  • Table 72. Europe Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 73. Europe Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 74. Europe Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 75. Europe Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 76. Germany Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 77. Germany Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 78. Germany Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 79. Germany Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 80. France Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 81. France Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 82. France Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 83. France Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 84. Italy Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 85. Italy Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 86. Italy Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 87. Italy Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 88. United Kingdom Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 89. United Kingdom Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 90. United Kingdom Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 91. United Kingdom Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 92. Netherlands Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 93. Netherlands Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 94. Netherlands Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 95. Netherlands Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 96. Rest of Europe Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 97. Rest of Europe Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 98. Rest of Europe Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 99. Rest of Europe Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 100. MEA Immunosuppressant Drugs, by Country USD Million (2018-2023)
  • Table 101. MEA Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 102. MEA Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 103. MEA Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 104. MEA Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 105. Middle East Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 106. Middle East Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 107. Middle East Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 108. Middle East Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 109. Africa Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 110. Africa Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 111. Africa Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 112. Africa Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 113. North America Immunosuppressant Drugs, by Country USD Million (2018-2023)
  • Table 114. North America Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 115. North America Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 116. North America Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 117. North America Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 118. United States Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 119. United States Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 120. United States Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 121. United States Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 122. Canada Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 123. Canada Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 124. Canada Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 125. Canada Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 126. Mexico Immunosuppressant Drugs, by End-users USD Million (2018-2023)
  • Table 127. Mexico Immunosuppressant Drugs, by Indication USD Million (2018-2023)
  • Table 128. Mexico Immunosuppressant Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 129. Mexico Immunosuppressant Drugs, by Drug Class USD Million (2018-2023)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Immunosuppressant Drugs: by End-users(USD Million)
  • Table 140. Immunosuppressant Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 141. Immunosuppressant Drugs Clinics , by Region USD Million (2025-2030)
  • Table 142. Immunosuppressant Drugs Others , by Region USD Million (2025-2030)
  • Table 143. Immunosuppressant Drugs: by Indication(USD Million)
  • Table 144. Immunosuppressant Drugs Organ Transplantation , by Region USD Million (2025-2030)
  • Table 145. Immunosuppressant Drugs Autoimmune Disorders , by Region USD Million (2025-2030)
  • Table 146. Immunosuppressant Drugs Non-autoimmune Inflammatory Diseases , by Region USD Million (2025-2030)
  • Table 147. Immunosuppressant Drugs: by Distribution Channel(USD Million)
  • Table 148. Immunosuppressant Drugs Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 149. Immunosuppressant Drugs Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 150. Immunosuppressant Drugs Online , by Region USD Million (2025-2030)
  • Table 151. Immunosuppressant Drugs Others , by Region USD Million (2025-2030)
  • Table 152. Immunosuppressant Drugs: by Drug Class(USD Million)
  • Table 153. Immunosuppressant Drugs Corticosteroids , by Region USD Million (2025-2030)
  • Table 154. Immunosuppressant Drugs Monoclonal Antibodies (mAbs) , by Region USD Million (2025-2030)
  • Table 155. Immunosuppressant Drugs Calcineurin Inhibitors , by Region USD Million (2025-2030)
  • Table 156. Immunosuppressant Drugs MTOR Inhibitors , by Region USD Million (2025-2030)
  • Table 157. Immunosuppressant Drugs Anti-Proliferative Agents , by Region USD Million (2025-2030)
  • Table 158. Immunosuppressant Drugs Others , by Region USD Million (2025-2030)
  • Table 159. South America Immunosuppressant Drugs, by Country USD Million (2025-2030)
  • Table 160. South America Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 161. South America Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 162. South America Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 163. South America Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 164. Brazil Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 165. Brazil Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 166. Brazil Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 167. Brazil Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 168. Argentina Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 169. Argentina Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 170. Argentina Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 171. Argentina Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 172. Rest of South America Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 173. Rest of South America Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 174. Rest of South America Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 175. Rest of South America Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 176. Asia Pacific Immunosuppressant Drugs, by Country USD Million (2025-2030)
  • Table 177. Asia Pacific Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 178. Asia Pacific Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 179. Asia Pacific Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 180. Asia Pacific Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 181. China Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 182. China Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 183. China Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 184. China Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 185. Japan Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 186. Japan Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 187. Japan Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 188. Japan Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 189. India Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 190. India Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 191. India Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 192. India Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 193. South Korea Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 194. South Korea Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 195. South Korea Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 196. South Korea Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 197. Taiwan Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 198. Taiwan Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 199. Taiwan Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 200. Taiwan Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 201. Australia Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 202. Australia Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 203. Australia Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 204. Australia Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 209. Europe Immunosuppressant Drugs, by Country USD Million (2025-2030)
  • Table 210. Europe Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 211. Europe Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 212. Europe Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 213. Europe Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 214. Germany Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 215. Germany Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 216. Germany Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 217. Germany Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 218. France Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 219. France Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 220. France Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 221. France Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 222. Italy Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 223. Italy Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 224. Italy Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 225. Italy Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 226. United Kingdom Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 227. United Kingdom Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 228. United Kingdom Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 229. United Kingdom Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 230. Netherlands Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 231. Netherlands Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 232. Netherlands Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 233. Netherlands Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 234. Rest of Europe Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 235. Rest of Europe Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 236. Rest of Europe Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 237. Rest of Europe Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 238. MEA Immunosuppressant Drugs, by Country USD Million (2025-2030)
  • Table 239. MEA Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 240. MEA Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 241. MEA Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 242. MEA Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 243. Middle East Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 244. Middle East Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 245. Middle East Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 246. Middle East Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 247. Africa Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 248. Africa Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 249. Africa Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 250. Africa Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 251. North America Immunosuppressant Drugs, by Country USD Million (2025-2030)
  • Table 252. North America Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 253. North America Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 254. North America Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 255. North America Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 256. United States Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 257. United States Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 258. United States Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 259. United States Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 260. Canada Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 261. Canada Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 262. Canada Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 263. Canada Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 264. Mexico Immunosuppressant Drugs, by End-users USD Million (2025-2030)
  • Table 265. Mexico Immunosuppressant Drugs, by Indication USD Million (2025-2030)
  • Table 266. Mexico Immunosuppressant Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 267. Mexico Immunosuppressant Drugs, by Drug Class USD Million (2025-2030)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immunosuppressant Drugs: by End-users USD Million (2018-2023)
  • Figure 5. Global Immunosuppressant Drugs: by Indication USD Million (2018-2023)
  • Figure 6. Global Immunosuppressant Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Immunosuppressant Drugs: by Drug Class USD Million (2018-2023)
  • Figure 8. South America Immunosuppressant Drugs Share (%), by Country
  • Figure 9. Asia Pacific Immunosuppressant Drugs Share (%), by Country
  • Figure 10. Europe Immunosuppressant Drugs Share (%), by Country
  • Figure 11. MEA Immunosuppressant Drugs Share (%), by Country
  • Figure 12. North America Immunosuppressant Drugs Share (%), by Country
  • Figure 13. Global Immunosuppressant Drugs share by Players 2023 (%)
  • Figure 14. Global Immunosuppressant Drugs share by Players (Top 3) 2023(%)
  • Figure 15. Global Immunosuppressant Drugs share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 21. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (United States) Revenue: by Geography 2023
  • Figure 25. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 27. Allergan, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Allergan, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 31. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Veloxis Pharmaceuticals A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 34. Veloxis Pharmaceuticals A/S (Denmark) Revenue: by Geography 2023
  • Figure 35. Global Immunosuppressant Drugs: by End-users USD Million (2025-2030)
  • Figure 36. Global Immunosuppressant Drugs: by Indication USD Million (2025-2030)
  • Figure 37. Global Immunosuppressant Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 38. Global Immunosuppressant Drugs: by Drug Class USD Million (2025-2030)
  • Figure 39. South America Immunosuppressant Drugs Share (%), by Country
  • Figure 40. Asia Pacific Immunosuppressant Drugs Share (%), by Country
  • Figure 41. Europe Immunosuppressant Drugs Share (%), by Country
  • Figure 42. MEA Immunosuppressant Drugs Share (%), by Country
  • Figure 43. North America Immunosuppressant Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis International AG (Switzerland)
  • Astellas Pharma Inc. (Japan)
  • Roche Holding AG (Switzerland)
  • Pfizer (United States)
  • Sanofi S.A. (France)
  • Allergan, Inc. (United States)
  • Bristol-Myers Squibb (United States)
  • AbbVie Inc. (United States)
  • Veloxis Pharmaceuticals A/S (Denmark)
Additional players considered in the study are as follows:
GlaxoSmithKline plc (United Kingdom)
Select User Access Type

Key Highlights of Report


Mar 2024 214 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Immunosuppressant Drugs Quantitative research analysis
Global Immunosuppressant Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Immunosuppressant Drugs Report?

Have a Query? Click Here

Other Related Reports

Rupatadine Comprehensive Study by Type (150 mg Tablets, 300 mg Tablets, Others), Application (Allergic Rhinitis, Urticaria), Dosage (Tablets, Capsules, Syrup), End User (Hospitals, Clinics) Players a...
$ 3500
Pharma Ophthalmic Comprehensive Study by Type (Prescription Drugs, Over-the-Counter Drugs), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Independent Pharmacies & Drug Stores), Therap...
$ 3750
Pompe Disease Treatment Comprehensive Study by Type (Infantile-onset Pompe Disease, Adult-Onset Pompe Disease), Therapy (Enzyme Replacement Therapy, Gene Therapy, Others), End User (Hospitals and Cli...
$ 3350
Medicinal Plant Extract Comprehensive Study by Type (Phytomedicines & Herbal Extracts, Flavors & Fragrances, Essential Oils, Spices), Application (Pharmaceuticals & Dietary Supplements, Cosmetics, Fo...
$ 3650
Myocardial Infarction Drugs Comprehensive Study by Type (Vasodilators {Nitrodilators, ACE Inhibitors, ARBs}, Cardiac depressant drugs {Beta Blockers}, Antiarrhythmics {Anti-thrombotics}, Thrombolytic...
$ 3650
Leiomyosarcoma Drug Comprehensive Study by Type (AL-3818, BGB-290, C-21, Others), Application (Clinic, Hospital, Others), Treatment (Surgery, Radiation therapy, Chemotherapy, Targeted drug therapy) P...
$ 3500